WORCESTER, Mass., Oct. 16, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has entered into a number of key service agreements for its global Phase III trials for Generex Oral-lyn, its proprietary oral insulin spray product. Generex has selected PSI-CRO AG Clinical Research Services (“PSI”) (www.psi-cro.com), a leading contract drug development company to serve as the company’s global clinical research organization (CRO) to provide full-service CRO services with 600-full-time staff in Europe and North America.
